Several seemingly minor safety issues could complicate the labeling discussions for Horizon Therapeutics PLC's teprotumumab, proposed for active thyroid eye disease (TED), a rare condition.
US Food and Drug Administration assessors did not indicate any of the adverse events mentioned could prevent or delay approval....